The specific binding of LC09 ensured the delivery of CRISPR/Cas9 to lung metastasis and orthotopic osteosarcoma [56], thus causing efficient VEGFA genome editing in cancer cells and inhibiting both types of tumors. Here, VEGFA is linked to cancer.